Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART) (NCT06280820) | Clinical Trial Compass
By InvitationNot Applicable
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
United States2,000 participantsStarted 2026-07-01
Plain-language summary
Background:
More than 6.5 million people in the United States live with heart failure (HF), and more than a million new cases are diagnosed each year. Treatments have improved in recent years, but researchers want to understand more about how HF develops. To do this, they need to compare blood and other samples from many people with HF.
Objective:
To collect blood and other samples from people with HF. These samples will be used to identify and study proteins and other factors that may lead to decreased heart function over time.
Eligibility:
People aged 18 years and older with heart failure.
Design:
Participants will be asked to join the study based on a review of their medical records.
They will have 1 study visit. They will provide a blood sample: About 3 tablespoons will be collected from a needle inserted into a vein.
Other tests are optional: Participants may provide urine and stool samples. They may have a cotton swab rubbed on the inside of the mouth to collect DNA.
Participants may also take 3 questionnaires. They will answer questions about dietary, social, and other factors that affect their health. Participants will receive compensation.
Researchers will follow the participants health by monitoring their medical records for up to 5 years.
Who can participate
Age range
18 Years – 100 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
* INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
* Clinical diagnosis of "active" HF documented by a cardiology provider's note in the medical record. Active HF is the presence of signs or symptoms that are deemed to be related to heart failure, as documented in the participants' medical records.
* Able and willing to undergo the consent process and provide consent
* Willing to comply with required study activities
* 18 years of age or older
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
* History of ventricular assist device
* History of cardiac transplant
* Living or residing outside of the geographic location designated for the study at the time of enrollment
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since MAP-HEART is focused on studying biological markers and their link to all-cause mortality in heart failure rather than testing a new treatment, what would I personally gain from participating, and would it affect my current care in any way?
2This trial is 'enrolling by invitation only' — what criteria are typically used to invite patients, and is there any reason my doctor might or might not put me forward for it?
3Because this study involves 'multi-omics' analysis, what types of biological samples would I need to provide — like blood, tissue, or urine — and how often, and would that add significant burden on top of my existing appointments?
4Since this appears to be an observational study rather than a treatment trial, how does participating here fit alongside my current heart failure treatment plan, and would it delay or change any of my standard care options?
5The study is measuring associations with all-cause mortality — if the researchers find something significant in my biological data, would I or my doctor ever be informed of those findings, and could they influence my treatment going forward?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
To study the association between multi-omics signatures with all-cause mortality
Timeframe: 10 years
Trial details
NCT IDNCT06280820
SponsorNational Heart, Lung, and Blood Institute (NHLBI)